FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306255113> ?p ?o ?g. }

• W4306255113 abstract "Abstract Background The obesity paradox has been reported in 3 post-hoc analyses evaluating the direct oral anticoagulants (DOAC) against warfarin (W): apixaban (ARISTOTLE), rivaroxaban (ROCKET), and edoxaban (ENGAGE-AF). Purpose To evaluate the obesity paradox in a post-hoc analysis of the RE-LY trial, comparing dabigatran 110 mg BID (D110), 150 mg BID (D150), and W by body mass index (BMI). Methods Baseline characteristics were evaluated using World Health Organization (WHO) criteria of overweight and obese (BMI ≥25 kg/m2) and under and normal weight (BMI &lt;25 kg/m2). Stroke and systemic embolism, ischemic stroke, major bleeding, mortality, and intracranial hemorrhage were evaluated using BMI as a continuous variable and by the WHO criteria using a cox proportional hazard model. Results BMI was available in 99.9% of patients randomized; 74% had a BMI ≥25. At baseline, patients with a BMI ≥25 were younger (70.9 vs 73.1, p&lt;0.001) and had fewer prior strokes (11.5% vs 15.6%, p&lt;0.001), but higher mean creatinine clearance (78.3 vs 57.0, p&lt;0.001) and rates of diabetes (25.8% vs 16.1%, p&lt;0.001) (Table 1). Independent of drug assignment, patients with a BMI ≥25 had lower rates of stroke and systemic embolism (HR 0.65 [95% CI 0.54–0.79], p&lt;0.001), ischemic stroke (0.75 [95% CI 0.60, 0.94], p=0.01), major bleeding (HR 0.79 [95% CI 0.69,0.89], p&lt;0.001), mortality (HR 0.60 [95% CI 0.53, 0.67], p&lt;0.001) and intracranial hemorrhage (HR 0.53 [95% CI 0.38, 0.73], p&lt;0.001) compared to those with a BMI &lt;25. Using BMI as a continuous variable combining all outcomes at 3 years, endpoint rates declined as BMI approached 25 in all 3 treatment groups. The exceptions were intracranial hemorrhage for D110 and D150 and stroke in D150 patients, where rates were low independent of BMI. No significant interaction between BMI and treatment was observed in individual outcomes except for the D110 vs. D150 comparison for major bleeding, in favor of D110 for patients with BMI ≥25 (HR 0.77 [95% CI 0.65, 0.91] and HR 1.12 [95% CI 0.86, 1.47], interaction p=0.0190). Conclusions In RE-LY, independent of drug assignment, patients with a higher BMI had improved outcomes, demonstrating the obesity paradox. As BMI increased towards 25, outcome rates improved except for intracranial hemorrhage rates for both D110 and D150 and ischemic stroke rates for D150, which were low independent of BMI. Patients treated with D110 with a BMI ≥25 kg/m2 had significantly lower rates of bleeding compared to D150. Funding Acknowledgement Type of funding sources: Foundation. Main funding source(s): Sharpe Strumia Foundation" @default.
• W4306255113 created "2022-10-15" @default.
• W4306255113 creator A5010306053 @default.
• W4306255113 creator A5013047382 @default.
• W4306255113 creator A5016763799 @default.
• W4306255113 creator A5028695564 @default.
• W4306255113 creator A5029533765 @default.
• W4306255113 creator A5031088308 @default.
• W4306255113 creator A5032400232 @default.
• W4306255113 creator A5038319783 @default.
• W4306255113 creator A5040825240 @default.
• W4306255113 creator A5063584322 @default.
• W4306255113 creator A5074949778 @default.
• W4306255113 creator A5074977968 @default.
• W4306255113 creator A5084746877 @default.
• W4306255113 date "2022-10-01" @default.
• W4306255113 modified "2023-10-18" @default.
• W4306255113 title "Body mass index from the RE-LY trial: further evidence of the obesity paradox" @default.
• W4306255113 doi "https://doi.org/10.1093/eurheartj/ehac544.629" @default.
• W4306255113 hasPublicationYear "2022" @default.
• W4306255113 type Work @default.
• W4306255113 citedByCount "0" @default.
• W4306255113 crossrefType "journal-article" @default.
• W4306255113 hasAuthorship W4306255113A5010306053 @default.
• W4306255113 hasAuthorship W4306255113A5013047382 @default.
• W4306255113 hasAuthorship W4306255113A5016763799 @default.
• W4306255113 hasAuthorship W4306255113A5028695564 @default.
• W4306255113 hasAuthorship W4306255113A5029533765 @default.
• W4306255113 hasAuthorship W4306255113A5031088308 @default.
• W4306255113 hasAuthorship W4306255113A5032400232 @default.
• W4306255113 hasAuthorship W4306255113A5038319783 @default.
• W4306255113 hasAuthorship W4306255113A5040825240 @default.
• W4306255113 hasAuthorship W4306255113A5063584322 @default.
• W4306255113 hasAuthorship W4306255113A5074949778 @default.
• W4306255113 hasAuthorship W4306255113A5074977968 @default.
• W4306255113 hasAuthorship W4306255113A5084746877 @default.
• W4306255113 hasBestOaLocation W43062551131 @default.
• W4306255113 hasConcept C126322002 @default.
• W4306255113 hasConcept C127413603 @default.
• W4306255113 hasConcept C207103383 @default.
• W4306255113 hasConcept C2776301958 @default.
• W4306255113 hasConcept C2778661090 @default.
• W4306255113 hasConcept C2779161974 @default.
• W4306255113 hasConcept C2780221984 @default.
• W4306255113 hasConcept C2780290652 @default.
• W4306255113 hasConcept C2780586474 @default.
• W4306255113 hasConcept C2780638905 @default.
• W4306255113 hasConcept C2780645631 @default.
• W4306255113 hasConcept C2781223611 @default.
• W4306255113 hasConcept C44249647 @default.
• W4306255113 hasConcept C511355011 @default.
• W4306255113 hasConcept C67761136 @default.
• W4306255113 hasConcept C71924100 @default.
• W4306255113 hasConcept C78519656 @default.
• W4306255113 hasConceptScore W4306255113C126322002 @default.
• W4306255113 hasConceptScore W4306255113C127413603 @default.
• W4306255113 hasConceptScore W4306255113C207103383 @default.
• W4306255113 hasConceptScore W4306255113C2776301958 @default.
• W4306255113 hasConceptScore W4306255113C2778661090 @default.
• W4306255113 hasConceptScore W4306255113C2779161974 @default.
• W4306255113 hasConceptScore W4306255113C2780221984 @default.
• W4306255113 hasConceptScore W4306255113C2780290652 @default.
• W4306255113 hasConceptScore W4306255113C2780586474 @default.
• W4306255113 hasConceptScore W4306255113C2780638905 @default.
• W4306255113 hasConceptScore W4306255113C2780645631 @default.
• W4306255113 hasConceptScore W4306255113C2781223611 @default.
• W4306255113 hasConceptScore W4306255113C44249647 @default.
• W4306255113 hasConceptScore W4306255113C511355011 @default.
• W4306255113 hasConceptScore W4306255113C67761136 @default.
• W4306255113 hasConceptScore W4306255113C71924100 @default.
• W4306255113 hasConceptScore W4306255113C78519656 @default.
• W4306255113 hasIssue "Supplement_2" @default.
• W4306255113 hasLocation W43062551131 @default.
• W4306255113 hasOpenAccess W4306255113 @default.
• W4306255113 hasPrimaryLocation W43062551131 @default.
• W4306255113 hasRelatedWork W1972269502 @default.
• W4306255113 hasRelatedWork W2003510779 @default.
• W4306255113 hasRelatedWork W2006773714 @default.
• W4306255113 hasRelatedWork W2032591458 @default.
• W4306255113 hasRelatedWork W2049934312 @default.
• W4306255113 hasRelatedWork W2085975373 @default.
• W4306255113 hasRelatedWork W2886710144 @default.
• W4306255113 hasRelatedWork W3016213733 @default.
• W4306255113 hasRelatedWork W3115978581 @default.
• W4306255113 hasRelatedWork W3197429252 @default.
• W4306255113 hasVolume "43" @default.
• W4306255113 isParatext "false" @default.
• W4306255113 isRetracted "false" @default.
• W4306255113 workType "article" @default.